Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient

Johanna Lotila; Tanja Hyvärinen; Heli Skottman; Laura Airas; Susanna Narkilahti; Sanna Hagman

doi:10.1016/j.scr.2022.102865

Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient

Johanna Lotila
, Tanja Hyvärinen
, Heli Skottman
, Laura Airas
, Susanna Narkilahti
, Sanna Hagman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Scientific › peer-review

6 Citations (Scopus)

42 Downloads (Pure)

Abstract

Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system where the main pathogenetic events include demyelination and axonal degeneration. Here, we generated a human induced pluripotent stem cell (hiPSC) line from peripheral blood mononuclear cells of an MS patient utilizing Sendai virus reprogramming. The produced hiPSC line expressed pluripotency markers, differentiated into three germ layers, showed a normal karyotype and was free of virus vectors, transgenes and mycoplasma. Established hiPSCs are a valuable source for studies of MS disease modeling and drug discovery.

Original language	English
Article number	102865
Number of pages	5
Journal	Stem Cell Research
Volume	63
DOIs	https://doi.org/10.1016/j.scr.2022.102865
Publication status	Published - Aug 2022
Publication type	A1 Journal article-refereed

Funding

This work was supported by Academy of Finland (SH 330707; 335937, SN 336665), Neurocenter Finland government funding (LA, SH, SN), The Finnish MS Foundation (SH, JL), the Päivikki ja Sakari Sohlberg Foundation (SH), the Finnish Cultural Foundation (SH) and the Doctoral Programme in Medicine, Biosciences and Biomedical Engineering, Tampere University (JL). The authors acknowledge the BioMediTech Virus Production Facility of Tampere University, Tampere Facility of Flow Cytometry, the Biocenter Finland (BF) and Tampere Imaging Facility (TIF) for their service. Moreover, the authors acknowledge Fimlab Laboratoriot Oy, Tampere, Finland, and the Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Finland, for their service. We thank Eija Hannuksela for her technical assistance with hiPSC line production, cell maintenance and analyses. We appreciate the technical guidance with hiPSC line production from Outi Melin and Hanna Pekkanen. Furthermore, we thank Iikka Veijola and Alli Lintunen for their technical assistance with analyses.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publication forum classification

Publication forum level 1

ASJC Scopus subject areas

Developmental Biology
Cell Biology

Access to Document

10.1016/j.scr.2022.102865Licence: CC BY

1-s2.0-S1873506122002148-mainFinal published version, 4.22 MBLicence: CC BY

https://urn.fi/URN:NBN:fi:tuni-202208206570Licence: CC BY

Cite this

@article{e79146b4189c41a195cf7f3515f6878c,

title = "Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient",

abstract = "Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system where the main pathogenetic events include demyelination and axonal degeneration. Here, we generated a human induced pluripotent stem cell (hiPSC) line from peripheral blood mononuclear cells of an MS patient utilizing Sendai virus reprogramming. The produced hiPSC line expressed pluripotency markers, differentiated into three germ layers, showed a normal karyotype and was free of virus vectors, transgenes and mycoplasma. Established hiPSCs are a valuable source for studies of MS disease modeling and drug discovery.",

author = "Johanna Lotila and Tanja Hyv{\"a}rinen and Heli Skottman and Laura Airas and Susanna Narkilahti and Sanna Hagman",

note = "Funding Information: This work was supported by Academy of Finland (SH 330707; 335937, SN 336665), Neurocenter Finland government funding (LA, SH, SN), The Finnish MS Foundation (SH, JL), the P{\"a}ivikki ja Sakari Sohlberg Foundation (SH), the Finnish Cultural Foundation (SH) and the Doctoral Programme in Medicine, Biosciences and Biomedical Engineering, Tampere University (JL). The authors acknowledge the BioMediTech Virus Production Facility of Tampere University, Tampere Facility of Flow Cytometry, the Biocenter Finland (BF) and Tampere Imaging Facility (TIF) for their service. Moreover, the authors acknowledge Fimlab Laboratoriot Oy, Tampere, Finland, and the Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Finland, for their service. We thank Eija Hannuksela for her technical assistance with hiPSC line production, cell maintenance and analyses. We appreciate the technical guidance with hiPSC line production from Outi Melin and Hanna Pekkanen. Furthermore, we thank Iikka Veijola and Alli Lintunen for their technical assistance with analyses. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = aug,

doi = "10.1016/j.scr.2022.102865",

language = "English",

volume = "63",

journal = "Stem Cell Research",

issn = "1873-5061",

publisher = "Elsevier",

}

TY - JOUR

T1 - Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient

AU - Lotila, Johanna

AU - Hyvärinen, Tanja

AU - Skottman, Heli

AU - Airas, Laura

AU - Narkilahti, Susanna

AU - Hagman, Sanna

N1 - Funding Information: This work was supported by Academy of Finland (SH 330707; 335937, SN 336665), Neurocenter Finland government funding (LA, SH, SN), The Finnish MS Foundation (SH, JL), the Päivikki ja Sakari Sohlberg Foundation (SH), the Finnish Cultural Foundation (SH) and the Doctoral Programme in Medicine, Biosciences and Biomedical Engineering, Tampere University (JL). The authors acknowledge the BioMediTech Virus Production Facility of Tampere University, Tampere Facility of Flow Cytometry, the Biocenter Finland (BF) and Tampere Imaging Facility (TIF) for their service. Moreover, the authors acknowledge Fimlab Laboratoriot Oy, Tampere, Finland, and the Institute for Molecular Medicine Finland FIMM Technology Centre, University of Helsinki, Finland, for their service. We thank Eija Hannuksela for her technical assistance with hiPSC line production, cell maintenance and analyses. We appreciate the technical guidance with hiPSC line production from Outi Melin and Hanna Pekkanen. Furthermore, we thank Iikka Veijola and Alli Lintunen for their technical assistance with analyses. Publisher Copyright: © 2022 The Author(s)

PY - 2022/8

Y1 - 2022/8

N2 - Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system where the main pathogenetic events include demyelination and axonal degeneration. Here, we generated a human induced pluripotent stem cell (hiPSC) line from peripheral blood mononuclear cells of an MS patient utilizing Sendai virus reprogramming. The produced hiPSC line expressed pluripotency markers, differentiated into three germ layers, showed a normal karyotype and was free of virus vectors, transgenes and mycoplasma. Established hiPSCs are a valuable source for studies of MS disease modeling and drug discovery.

AB - Multiple sclerosis (MS) is a complex autoimmune disease of the central nervous system where the main pathogenetic events include demyelination and axonal degeneration. Here, we generated a human induced pluripotent stem cell (hiPSC) line from peripheral blood mononuclear cells of an MS patient utilizing Sendai virus reprogramming. The produced hiPSC line expressed pluripotency markers, differentiated into three germ layers, showed a normal karyotype and was free of virus vectors, transgenes and mycoplasma. Established hiPSCs are a valuable source for studies of MS disease modeling and drug discovery.

U2 - 10.1016/j.scr.2022.102865

DO - 10.1016/j.scr.2022.102865

M3 - Article

AN - SCOPUS:85134302310

SN - 1873-5061

VL - 63

JO - Stem Cell Research

JF - Stem Cell Research

M1 - 102865

ER -

Establishment of a human induced pluripotent stem cell line (TAUi008-A) derived from a multiple sclerosis patient

Abstract

Funding

UN SDGs

Publication forum classification

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this